This clinical study tests a new medicine called amlitelimab to see if it helps people aged 12 and older with moderate-to-severe atopic dermatitis (AD), a skin condition causing red, itchy patches. The study compares amlitelimab to a placebo, which looks like real medicine but doesn’t contain any active ingredients. Participants who don't respond well to creams or other treatments can join. The study lasts up to 44 weeks, with up to 10 clinic visits.

• The main treatment lasts 24 weeks; there’s a 16-week follow-up for some.
• Participants can join an extension study lasting 28 weeks with 9 visits.
• Eligibility includes being 12 years or older and having AD for at least a year.

Before joining, doctors will ensure participants don't have other serious health issues, like infections or a history of cancer, which might affect the study. It’s important to talk to a doctor to decide if participating is right for you.